TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evgen Pharma ( (GB:TCF) ) has provided an announcement.
TheraCryf plc announced that Northern Standard Limited, a company in which Non-Executive Director Ed Wardle holds a 49% interest, has purchased 7,342,296 ordinary shares of the company. This acquisition increases Mr. Wardle’s interest to 20.01% of the company’s issued ordinary shares, potentially strengthening his influence within the company and signaling confidence in TheraCryf’s strategic direction.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.
To see Spark’s full report on GB:TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a clinical stage drug development company focusing on brain disorders. It has a broad clinical and preclinical pipeline targeting conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company’s strategy involves generating compelling data sets to achieve preclinical or clinical proof of concept and partnering with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is quoted on AIM in London under the ticker symbol TCF.
Average Trading Volume: 5,148,786
Technical Sentiment Signal: Sell
Current Market Cap: £4.51M
For detailed information about TCF stock, go to TipRanks’ Stock Analysis page.